^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GZMA underexpression

    i
    Other names: GZMA, Granzyme A, CTL Tryptase, Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated Serine Esterase 3), Cytotoxic T-Lymphocyte-Associated Serine Esterase-3, Cytotoxic T-Lymphocyte Proteinase 1, Hanukah Factor Serine Protease, Fragmentin-1, Granzyme 1, H Factor, CTLA3, HFSP, HF, Granzyme A (Cytotoxic T-Lymphocyte-Associated Serine Esterase-3; Hanukah Factor Serine Protease), Hanukkah Factor, Granzyme-1
    Entrez ID:
    3001
    Related biomarkers:
    Expression
    2ms
    An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma. (PubMed, Front Immunol)
    Advanced gastric adenocarcinoma patients received β-glucan, camrelizumab, oxaliplatin, oral S-1 every 3 weeks...This preliminary study demonstrates that β-glucan plus camrelizumab and SOX chemotherapy offers favorable efficacy and a manageable safety profile in patients with advanced gastric adenocarcinoma, and further studies are needed to verify its efficacy and safety. Chinese Clinical Trials Registry, identifier ChiCTR2100044088.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • GZMA (Granzyme A)
    |
    GZMA underexpression
    |
    AiRuiKa (camrelizumab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)